Aug 24, 2018   SOURCE: PR NewsWire

2018 Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report

DUBLIN, Aug. 24, 2018 /PRNewswire/ --

The "Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (PARP, PD-L1 Inhibitors , Angiogenesis), By Major Markets (U.S., U.K., Germany, Spain, Italy, France, Japan), And Segment Forecasts, 2016 - 2022" report has been added to ResearchAndMarkets.com's offering.

The global ovarian cancer drugs market size is expected to be valued at USD 4.5 billion by 2022, expanding at a CAGR of 23.7% during the forecast period.

The growth of the market is largely driven by factors such as increased adoption of novel drugs and presence of strong pipeline. Rising incidence of ovarian cancer due to growing geriatric population and unhealthy lifestyles is providing an upthrust to the market.

Ovarian cancer accounts for 3.0% of all malignant tumors among women and 6.0% of all femaledeaths due to cancer. Ovarian cancer accounted for 235,200 new cases and 140,000 deaths worldwide in 2016 with the highest incidence being reported in North America and Europe.

Introduction of non-platinum based PARP inhibitors and VEGF inhibitors in second and third-line settings has changed the treatment regime for ovarian cancer dramatically. Several biologic and small-molecule therapies including antibody drug conjugates (ADC) in development are estimated to have a major impact on ovarian cancer treatment spectrum.

Further key findings from the report suggest:

    --  EU5 is projected to be the second largest market with more than 10.0%
        share in 2022, owing to increasing ovarian cancer incidence and approval
        of PARP inhibitors
    --  Key players in the industry are focusing on collaborations for
        development, broader product portfolios, and regional expansion in
        emerging markets to increase their market share
    --  Combination regimens and pipeline breakthroughs, specifically those
        including checkpoint inhibitors such as Roche's Tecentriq and Pfizer's
        Bavencio, are poised to be the upcoming milestones for ovarian cancer
        treatment
    --  PARP inhibitors are anticipated to be the fastest growing drug class in
        the ovarian cancer market through the forecast period. Factors such as
        continued uptake of approved PARP inhibitors owing to their superior
        efficacy, long treatment duration, and considerable number of treatment
        opportunities in first-line advanced settings are likely to propel the
        growth of the drug class.
    --  Although angiogenesis inhibitors accounted for the majority of shares in
        the market in 2016, the drug class is expected to capture a marginal
        share in 2022 owing to increasing competition from PARP inhibitors and
        novel pipeline products
    --  Out of 78 drugs in the pipeline for ovarian cancer, 11 drugs are in
        Phase III, 29 in Phase II and the remaining in Phase I and pre-clinical
        trials
    --  A greater understanding of tumor microenvironment is estimated to occur,
        which would further drive successful development of new patient-specific
        therapies through the forecast period
    --  Late-stage pipeline includes novel drugs such as ImmunoGen's
        mirvetuximab soravtansine and Vascular Biogenics' VBL-111.

Key Topics Covered:

Chapter 1 Research Methodology
1.1. Information Procurement
1.2. Information or Data Analysis
1.2.1 Market Formulation & Validation

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology
3.1. Disease Primer and Epidemiology
3.1.1. Current Prevalence Rate and Incidence Rate for Seven Major Markets (U.S., Japan, EU5)

Chapter 4 Global Ovarian Cancer Drugs Market Overview
4.1 Major Therapeutic Classes for Ovarian Cancer
4.2 Market, by Therapeutic Class
4.3 Sales Performance, by Therapeutic Class (2016 - 2022)
4.3.1. PARP Inhibitors
4.3.2. Angiogenesis Inhibitors
4.3.3. PD-L1 Inhibitors
4.4 Market Size and Forecast (2016- 2022)
4.5 Market Size and Forecast, by Seven Major Markets (2016- 2022)
4.5.1 U.S., Sales by Therapeutic Class (2016 - 2022)
4.5.2 U.K., Sales by Therapeutic Class (2016 - 2022)
4.5.3 Germany, Sales by Therapeutic Class (2016 - 2022)
4.5.4 France, Sales by Therapeutic Class (2016 - 2022)
4.5.5 Italy, Sales by Therapeutic Class (2016 - 2022)
4.5.6 Spain, Sales by Therapeutic Class (2016 - 2022)
4.5.7 Japan, Sales by Therapeutic Class (2016 - 2022)
4.6 Market Share Distribution, by Company (2016- 2022)
4.7 Market Dynamics and Brand Strategies
4.8 Patent Expiry Analysis
4.9 Ovarian Cancer Market: Drivers and Restraints
4.9.1 Market Drivers
4.9.2 Market Restraints
4.10. M&A, Deal Landscape (2013-2017 YTD)
4.10.1 Mergers & Acquisitions
4.10.2 Deals Landscape
4.11. Evolution of Biosimilars
4.12. Emerging Markets
4.13. Pricing and Reimbursement Scenario
4.14. Ovarian Cancer Sector SWOT

Chapter 5 Ovarian Cancer Drugs Market: Pipeline Intelligence
5.1. Pipeline Landscape
5.1.1 Leading Drugs in Development
5.1.2 Key R&D Trends
5.2 Key R&D Trends
5.3 Pipeline Landscape
5.3.1 Late Stage Pipeline and Sales Forecast
5.4 Clinical Profiles of Disruptive Drugs
5.5 Global Pipeline Forecast

Chapter 6 Company Profiles
6.1 AstraZeneca
6.2 Roche/ Genentech
6.3 Tesaro
6.4 Clovis Oncology

Chapter 7 Market Outlook
7.1 What the Future Holds
7.2 The Winners and Losers
7.2.1 Winners
7.2.2 Losers
7.3 Emerging Companies & Technology Platforms
7.4 The Road Ahead

For more information about this report visit https://www.researchandmarkets.com/research/d9nnd4/2018_ovarian?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content with multimedia:http://www.prnewswire.com/news-releases/2018-ovarian-cancer-drugs-market-size-share--trends-analysis-report-300702067.html

SOURCE Research and Markets